Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA 3 study results on rilzabrutinib’s capability to treat the underlying immune dysregulation in ITP. An oral presentation reported rates of platelet response according to International Working Group (IWG) criteria—a major clinical endpoint for making treatment decisions. Two poster presentations reported the first efficacy and safety results from […]
Sanofi
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Tolebrutinib was generally well tolerated by all subjects across all study arms.
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
